QuidelOrtho Corp (QDEL) Stock AnalysisQDELQuidelOrtho Corp

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

QuidelOrtho Corp (QDEL) is currently trading at $12.91, which is below the average analyst price target of $18.63, indicating potential for growth. However, the company has a significant net debt of approximately $2.6 billion, which poses a risk to its financial stability. The RSI is at 50.026, suggesting the stock is neither overbought nor oversold, and the recent insider buying activity has surged by 2578.44%, indicating confidence from management. Given these factors, it may be prudent to hold rather than buy at this time while monitoring for further developments regarding the potential sale of its testing business and overall market conditions.

7 analysts cover QDEL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.